Emerging evidence indicates that activation of STAT3 is one of the contributors to EGFR-TKI resistance, and targeted inhibition of STAT3 signaling has shown potential to circumvent therapeutic resistance both in lung cancer and other malignancies [14, 15]. The gene discussed is STAT3; the disease is lung cancer.